LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm, in collaboration with Lindis Biotech, is developing Catumaxomab for use in a broad range of cancers globally. Additionally, LintonPharm is developing a next generation bispecific antibody platform to provide a more robust manufacturing and drug design and increased flexibility to individualize the design of each molecule. The current pipeline includes several treatments in development for blood cancer and solid tumors.

We have an industry-leading management team and scientific advisors with rich experience in cancer immunotherapy especially T cell engagers, and with antibody engineering, advancing drug candidates from early-stage research to clinical trials and regulatory approval.

Guided by our core value – science and conscience, we relentlessly build on our expertise in cancer immunology and leading-edge technologies in pursuit of transformative and affordable treatments for cancer patients. We approach each day with our commitment and passion to improve lives of patients, and a sense of humility, recognizing that our strength resides in the diversity of our journeys and the opportunity to learn from each other.